[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100207015":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":23,"locations":24,"responsibleParty":36,"collaborators":23,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":23,"acronym":23,"eligibilityCriteria":43,"healthyVolunteers":40,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":23,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":58,"whyStopped":23,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"Yonsei University","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"Rosuvastatin group","EXPERIMENTAL",[12],"Drug: Rosuvastatin",{"label":14,"type":15,"description":14,"interventionNames":16},"Placebo group","PLACEBO_COMPARATOR",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Rosuvastatin","Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.\n\nA) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.\n\nB) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.",[14,9],null,[25],{"facility":26,"status":23,"city":27,"state":23,"zip":28,"country":29,"countryCode":23,"cosmosGeoPoint":30,"geoPoint":35,"contacts":23},"Division of Cardiovascular Surgery, Severance Cardiovascular Hospital , Yonsei University College of Medicine","Seoul","120-752","South Korea",{"type":31,"coordinates":32},"Point",[33,34],126.9784,37.566,{"lat":34,"lon":33},{"type":37,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100207015","phase-4-impact-of-high-dose-pretreatment-of-rosuvastatin-in-patients-with-acute-coronary-syndrome-following-off-pump-coronary-artery-bypass-results-from-the-hirop-acs-high-dose-pretreatment-of-rosuvastatin-during-off-pump-coronary-bypass-in-acute-coronary-syndrome-study-100207015",false,"NCT01971606","Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study","Inclusion Criteria:\n\n* The presence of acute coronary syndrome, including unstable angina, acute non-ST elevation myocardial infarction\n* Age of 19 years or older\n* A need for isolated surgical myocardial revascularization\n* Patients with signed informed consent\n\nExclusion Criteria:\n\n* Patients with combined surgery with coronary bypass grafting\n* On-pump conversion\n* Patients with any increase in liver enzymes\n* Patients with history of liver or muscle disease.\n* Patients with moderate renal dysfunction (creatinine\\>2.0mg\u002Fdl) or need for dialysis\n* Re-do surgery\n* Urgent\u002Femergent surgery","ALL","19 Years","90 Years",{"count":48,"type":49},234,"ACTUAL","INTERVENTIONAL",[52],"PHASE4","Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic effects, such as anti-thrombotic and anti-inflammatory actions.\n\n-Objective: to determine whether preoperative rosuvastatin loading is independently associated with reduced myocardial ischemia and clinical outcomes in patients with stable angina undergoing isolated off-pump coronary bypass (OPCAB) in patients with acute coronary syndrome.\n\nStudy design\n\n* Prospective, double-blinded, single-center study of each 117 subjects enrolled\n* Subjects with acute coronary syndrome who meet all inclusion and exclusion criteria will be enrolled preoperatively.\n* Eligible subjects will be randomized 1:1 to A) High-dose rosuvastatin (n=117) vs. B) Placebo (n=117).\n* The amount of preoperative administration of high-dose rosuvastatin will be 60mg of a total\n* All subjects will undergo OPCAB procedure. - The primary and secondary endpoints will be compared at 30 days and 2 years postoperatively between two groups",[55],"A Total of 234 Patients With Acute Coronary Syndrome Who Will Undergo OPCAB.",[57],"Statin, coronary artery bypass grafting, off-pump surgery, acute coronary syndrome","COMPLETED","2013-10-31",{"date":61,"type":62},"2013-11-01","ESTIMATED",{"date":64,"type":23},"2007-10",{"date":66,"type":49},"2013-03",{"name":5,"class":6},1]